Novavax (NasdaqGS:NVAX) recently announced its earnings for Q4 2024, showing a significant improvement in net loss and loss per share, which may have positively influenced its stock price movement.

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Shares of Novavax Inc. NVAX advanced 5.97% to $8.34 Friday, on what proved to be an all-around positive trading session for ...

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

B. Riley cut their Q1 2025 earnings per share estimates for Novavax in a report issued on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the ...